Navigation Links
QuantaLife Announces Launch of Droplet Digital™ PCR System
Date:11/2/2010

WASHINGTON, Nov. 2, 2010 /PRNewswire/ -- QuantaLife, Inc. announced today at the 60th Annual American Society of Human Genetics Meeting the launch of their Droplet Digital™ PCR system. The system, which includes a droplet generator and a droplet reader, quantifies DNA molecules using the company's patented high-resolution, Droplet Digital PCR technology – a 3rd generation PCR technology that enables single-molecule resolution of target sequences.

Droplet Digital PCR uses microfluidics to partition each sample into 20,000 to millions of one-nanoliter droplets, each of which contains a separate PCR. The droplets are streamed in single file past a detector to count the negative and positive reactions.

The QuantaLife system introduces a new era of high performance PCR testing. The system detects slight differences in gene copy number (i.e., 6 copies from 5), or a 10% difference in mRNA expression. There is no need for a standard. The system can read 48 samples per hour.

Serge Saxonov, Ph.D, Vice President of Application Development at QuantaLife will present results obtained using the QuantaLife system at the ASHG meeting. The seminar titled "Introducing the 3rd Generation of PCR: droplet digital PCR – A New System for CNV Detection," will be held Friday, November 5, 2010 at 12:30 pm at the Grand Hyatt Washington, Lafayette Room, 1000 H Street NW, Washington, DC.

More information about QuantaLife and the Droplet Digital PCR system is available at www.quantalife.com.

About QuantaLife

QuantaLife has developed the 3rd generation of PCR technology that quantifies DNA molecules by Droplet Digital™ PCR . Droplet Digital PCR provides an absolute measure of target molecules with unrivaled quantitative resolution and sensitivity. Applications include copy number variation (CNV), mutation detection, and gene expression analysis. Our mission is to provide tools that accelerate new strategies for the diagnosis and treatment of inherited disorders, cancer, and infectious disease.Contact:Mike LuceroQuantaLife, Inc.+1-650-823-6366
'/>"/>

SOURCE QuantaLife, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. QuantaLife, Inc. Unanimously Selected as the Most Promising Company at the Personalized Medicine World Conference 2010
2. China-Biotics, Inc. Announces Conference Call to Discuss First Quarter 2009 Financial Results
3. Odyssey Thera Announces Milestone Achievement in Pfizer Alliance
4. InNexus Biotechnology Announces Launch of Large Scale Primate Study of DXL625
5. Anesiva Announces Second Quarter 2008 Financial Results and Update
6. SGX Pharmaceuticals Announces Financial Results for the Three and Six Months Ended June 30, 2008
7. Insmed Announces Financial Results for Second Quarter and Six-Months Ended June 30, 2008
8. China Sky One Medical, Inc. Announces Conference Call to Discuss Second Quarter 2008 Results
9. China Yingxia International, Inc. Announces Conference Call to Discuss Second Quarter 2008 Results
10. ThirdBiotech Announces Kemeta as Newest Sponsor
11. Signalife Announces Intent to Withdraw From AMEX and Trade on the OTCBB
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... ... October 12, 2017 , ... ... with the addition of its newest module, US Hemostats & Sealants. , SmartTRAK’s ... hemostats, absorbable hemostats, fibrin sealants, synthetic sealants and biologic sealants used in surgical ...
(Date:10/11/2017)... ... October 11, 2017 , ... ... in its endogenous context, enabling overexpression experiments and avoiding the use of exogenous ... RNA guides is transformative for performing systematic gain-of-function studies. , This complement ...
(Date:10/11/2017)... 2017  VMS BioMarketing, a leading provider of patient support ... Nurse Educator (CNE) network, which will launch this week. The ... health care professionals to enhance the patient care experience by ... other health care professionals to help women who have been ... ...
(Date:10/11/2017)... ... October 11, 2017 , ... Singh Biotechnology today ... designation to SBT-100, its novel anti-STAT3 (Signal Transducer and Activator of Transcription 3) ... able to cross the cell membrane and bind intracellular STAT3 and inhibit its ...
Breaking Biology Technology:
(Date:4/11/2017)... -- NXT-ID, Inc. (NASDAQ:   NXTD ) ("NXT-ID" ... of independent Directors Mr. Robin D. Richards and ... furthering the company,s corporate governance and expertise. ... Gino Pereira , Chief Executive Officer ... guidance and benefiting from their considerable expertise as we move ...
(Date:4/4/2017)... , April 4, 2017   EyeLock LLC ... announced that the United States Patent and Trademark Office ... broadly covers the linking of an iris image with ... transaction) and represents the company,s 45 th issued ... patent is very timely given the multi-modal biometric capabilities ...
(Date:3/29/2017)... 29, 2017  higi, the health IT company that ... North America , today announced a Series B ... of EveryMove. The new investment and acquisition accelerates higi,s ... to transform population health activities through the collection and ... higi collects and secures data today on behalf ...
Breaking Biology News(10 mins):